154 related articles for article (PubMed ID: 37450876)
1. The Use of Botulinum Toxin in Raynaud Phenomenon: A Comprehensive Literature Review.
Lawson O; Sisti A; Konofaos P
Ann Plast Surg; 2023 Jul; 91(1):159-186. PubMed ID: 37450876
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
Fregene A; Ditmars D; Siddiqui A
J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
[TBL] [Abstract][Full Text] [Related]
3. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin A treatment of Raynaud's phenomenon: a review.
Iorio ML; Masden DL; Higgins JP
Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066
[TBL] [Abstract][Full Text] [Related]
5. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
[TBL] [Abstract][Full Text] [Related]
6. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
Nagarajan M; McArthur P
Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
[TBL] [Abstract][Full Text] [Related]
7. A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer.
Wang L; Lei QS; Liu YY; Song GJ; Song CL
Medicine (Baltimore); 2016 Oct; 95(40):e5092. PubMed ID: 27749585
[TBL] [Abstract][Full Text] [Related]
8. Botulinum Toxin A Treatment for Primary and Secondary Raynaud's Phenomenon in Teenagers.
Quintana Castanedo L; Feito Rodríguez M; Nieto Rodríguez D; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
Dermatol Surg; 2021 Jan; 47(1):61-64. PubMed ID: 32371783
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
Uppal L; Dhaliwal K; Butler PE
J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Neumeister MW
J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
[TBL] [Abstract][Full Text] [Related]
12. The Role of Botulinum Toxin A in the Treatment of Raynaud Phenomenon.
Segreto F; Marangi GF; Cerbone V; Persichetti P
Ann Plast Surg; 2016 Sep; 77(3):318-23. PubMed ID: 26808752
[TBL] [Abstract][Full Text] [Related]
13. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Bello RJ; Cooney CM; Melamed E; Follmar K; Yenokyan G; Leatherman G; Shah AA; Wigley FM; Hummers LK; Lifchez SD
Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903
[TBL] [Abstract][Full Text] [Related]
14. Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon.
Gallegos JE; Inglesby DC; Young ZT; Herrera FA
J Hand Surg Am; 2021 Jan; 46(1):54-59. PubMed ID: 32948347
[TBL] [Abstract][Full Text] [Related]
15. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin.
Quintana Castanedo L; Feito Rodríguez M; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
Pediatr Dermatol; 2020 Jul; 37(4):681-683. PubMed ID: 32212180
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
[TBL] [Abstract][Full Text] [Related]
17. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
Dhaliwal K; Griffin M; Denton CP; Butler PEM
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
Ennis D; Ahmad Z; Anderson MA; Johnson SR
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Habib SM; Brenninkmeijer EEA; Vermeer MH; de Vries-Bouwstra JK; Velthuis PJ
Dermatol Ther; 2020 Nov; 33(6):e14182. PubMed ID: 32794364
[TBL] [Abstract][Full Text] [Related]
20. The role of botulinum toxin in vasospastic disorders of the hand.
Neumeister MW
Hand Clin; 2015 Feb; 31(1):23-37. PubMed ID: 25455354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
